Kappa-opiates and urination: pharmacological evidence for an endogenous role of the kappa-opiate receptor in fluid and electrolyte balance.
In prehydrated rats, the administration of kappa-opiate agonists such as bremazocine, ethylketocyclazocine or compound Upjohn-50,488 produced a dose-dependent increase in urine output and decreased the concentration of Na+ and K+ in the urine as compared to that of saline-treated rats. The diuretic effect of bremazocine lasted at least 3 h. The increase in urine output was independent of the hydration state of the rat since in non water-loaded animals, bremazocine produced proportionally as much diuresis and a decrease in the output of urine electrolytes of about the same magnitude as that observed in the prehydrated animals treated with the opioid. In contrast to the diuretic action of kappa-opiate agonists, the administration of antagonists with high affinity for the kappa-opiate receptor (Win 44,441 or Mr 2266) decreased dose dependently the output of urine and reduced very significantly the total output of Na+ and K+. Whereas 2 mg/kg naloxone did not block the bremazocine-induced urinary effects, 1 mg/kg Win 44,441 or Mr 2266 antagonized competitively the renal activity of bremazocine. The results are interpreted to suggest that the kappa-opiate receptor may be involved in the regulation of fluid and electrolyte balance.
D000818:Animals; D001392:Azocines / Q000494:pharmacology; D001575:Benzomorphans / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D003496:Cyclazocine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004231:Diuresis / Q000187:drug effects*; D016314:Ethylketocyclazocine; D005260:Female; D007274:Injections, Intraperitoneal; D009019:Morphinans / Q000494:pharmacology*; D009020:Morphine / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D011188:Potassium / Q000652:urine; D051381:Rats; D011919:Rats, Inbred Strains; D011957:Receptors, Opioid / Q000187:drug effects; D012964:Sodium / Q000652:urine; D014882:Water-Electrolyte Balance / Q000187:drug effects
D001392:Azocines; D001575:Benzomorphans; D009019:Morphinans; D011957:Receptors, Opioid; D009270:Naloxone; C027247:MR 2266; D016314:Ethylketocyclazocine; D009020:Morphine; D012964:Sodium; C027248:bremazocine; D003496:Cyclazocine; D011188:Potassium; C035969:quadazocine